



CLAIMS

1. A compound represented by general formula (I):





[wherein,




5

represents:



represents:



10

and X represents CH or N];

a salt thereof, a solvate thereof or an N-oxide thereof.

2. The compound according to claim 1, wherein the compound represented by general formula (I) is (3S)-3-[5-(6-amino-2-fluoro-3-pyridinyl)-4-fluoro-1H-imidazol-2-yl]-7-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2,3-dihydro-5(1H)-indolizinone, a salt thereof, a solvate thereof or an N-oxide thereof.

3. The compound according to claim 1, wherein the compound represented by general formula (I) is (3S)-3-[2-(6-amino-2-fluoro-3-pyridinyl)-4-fluoro-1H-imidazol-5-yl]-7-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2,3-dihydro-5(1H)-indolizinone, a salt thereof, a solvate thereof or an N-oxide thereof.

4. The compound according to claim 1, wherein the compound represented by general formula (I) is (6S)-6-[2-(6-amino-2-fluoro-3-pyridinyl)-4-fluoro-1H-imidazol-5-yl]-2-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-7,8-dihydropyrrolo[1,2-a]pyrimidin-4(6H)-one, a salt thereof, a solvate thereof or an N-oxide thereof.

5. The compound according to claim 1, wherein the compound represented by general formula (I) is 1-(2-{(3S)-3-[5-(4-aminophenyl)-4-fluoro-1H-imidazol-2-yl]-5-oxo-1,2,3,5-tetrahydro-7-indolizinyl}-4-chlorophenyl)-1H-1,2,3-triazole-4-carbonitrile, a salt thereof, a solvate thereof or an N-oxide thereof.

6. A pharmaceutical composition comprising the compound according to any one of claims 1 to 5, a salt thereof, a solvate thereof or an N-oxide thereof as an active ingredient.

7. An FXIa inhibitor comprising the compound according to any one of claims 1 to 5, a salt thereof, a solvate thereof or an N-oxide thereof as an active ingredient.

8. An agent for preventing and/or treating thromboembolic disease, comprising the compound according to any one of claims 1 to 5, a salt thereof, a solvate thereof or an N-oxide thereof as an active ingredient.

9. The agent according to claim 8, wherein the

thromboembolic disease is arterial cardiovascular
thromboembolic disorder, venous cardiovascular
thromboembolic disorder, arterial cerebrovascular
thromboembolic disorder, venous cerebrovascular
5 thromboembolic disorder or thromboembolic disorder in the
heart chamber or in the peripheral circulation.

10 10. The agent according to claim 8 or 9, wherein
the thromboembolic disease is coronary artery disease,
unstable angina, acute coronary syndrome, atrial
fibrillation, myocardial infarction, ischemic sudden
death, transient ischemic attack, cerebral stroke,
peripheral arterial disease, atherosclerosis, peripheral
occlusive arterial disease, venous thrombosis, venous
thromboembolism, deep venous thrombosis,
15 thrombophlebitis, arterial embolism, coronary artery
thrombosis, cerebral arterial thrombosis, cerebral
embolism, kidney embolism, portal vein thrombosis,
pulmonary embolism, pulmonary infarction, liver embolism,
hepatic veno-occlusive disease/sinusoidal obstruction
20 syndrome, thrombotic microangiopathy, disseminated
intravascular coagulation, sepsis, acute respiratory
distress syndrome, acute lung injury, antiphospholipid
antibody syndrome, thrombosis resulting from coronary
artery bypass graft surgery or thrombosis induced by
25 treatment in which blood is exposed to an artificial
surface which promotes thrombus formation.

30 11. The agent according to any one of claims 8 to
10, wherein the thromboembolic disease is venous
thromboembolism, ischemic stroke, thromboembolic disease
induced by treatment in which blood is exposed to an
artificial surface which promotes thrombus formation,
acute coronary syndrome, coronary artery disease or
peripheral arterial disease.

35 12. The compound according to any one of claims 1
to 5, a salt thereof, a solvate thereof or an N-oxide
thereof for preventing and/or treating thromboembolic
disease.

13. Use of the compound according to any one of claims 1 to 5, a salt thereof, a solvate thereof or an N-oxide thereof for manufacture of an agent for preventing and/or treating thromboembolic disease.

5

10

15

20

25

30

35